On February 18, 2020 Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care Products", reported that its Board of Directors, consistent with its transformation into a consumer self-care company, approved a 7% increase to the company’s quarterly dividend to $0.225 per share from $0.21 per share (Press release, Perrigo Company, FEB 18, 2020, View Source [SID1234554435]). This dividend increase marks the 17th consecutive year Perrigo has increased its dividend.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The cash dividend is payable on March 17, 2020 to shareholders of record on February 28, 2020.

On February 18, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported that company management will participate at the upcoming Cowen 40th Annual Health Care Conference (Press release, Personalis, FEB 18, 2020, View Source [SID1234554451]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

John West, Chief Executive Officer, will be presenting on Wednesday, March 4, 2020 at 8:40 a.m. Eastern Time at the Boston Marriott Copley Place hotel in Boston.

On February 18, 2020 Luminex Corporation (Nasdaq:LMNX) (the "Company") reported that its board of directors declared a cash dividend for the first quarter of 2020 of $0.09 per share of common stock payable on April 9, 2020 to stockholders of record as of the close of business March 19, 2020 (Press release, Luminex, FEB 18, 2020, View Source [SID1234554467]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 18, 2020 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that the company is scheduled to present at the Cowen 40th Annual Healthcare Conference in Boston on Tuesday, March 3, 2020 at 11:20 a.m. ET (Press release, Agios Pharmaceuticals, FEB 18, 2020, https://investor.agios.com/news-releases/news-release-details/agios-present-cowen-40th-annual-healthcare-conference-tuesday [SID1234554420]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation

On February 18, 2020 RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, reported that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020, at 10:00 a.m. EST, at the Lotte New York Palace, New York (Press release, RedHill Biopharma, FEB 18, 2020, View Source [SID1234554436]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be broadcast live and available via replay for 30 days on the Company’s website, View Source Please access the website at least 15 minutes ahead of the conference call to register.